Form 4: GeneDx Holdings CEO Sells Shares
Insider Transaction (Form 4)
Katherine Stueland, CHIEF EXECUTIVE OFFICER and a Director of GeneDx Holdings Corp., sold 10,501 shares of common stock on September 16, 2026.
Summary
- Option exercise/conversion: acquired 18,750 Class A Common Stock on September 16, 2026; holds 125,977 after (Direct).
- Open-market sale: disposed of 1,648 Class A Common Stock at $94.26 ($155,337) on September 16, 2026; holds 124,329 after (Direct).
- Open-market sale: disposed of 148 Class A Common Stock at $95.41 ($14,120) on September 16, 2026; holds 124,181 after (Direct).
- Open-market sale: disposed of 1,525 Class A Common Stock at $96.90 ($147,774) on September 16, 2026; holds 122,656 after (Direct).
- Open-market sale: disposed of 4,141 Class A Common Stock at $98.27 ($406,936) on September 16, 2026; holds 118,515 after (Direct).
- Open-market sale: disposed of 3,039 Class A Common Stock at $99.00 ($300,846) on September 16, 2026; holds 115,476 after (Direct).
- Option exercise/conversion: disposed of 18,750 Restricted Stock Unit on September 16, 2026; holds 37,500 after (Direct).
Sentiment
Score: 3
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $1,025,013 of stock on the open market.
Insider Transactions
Katherine Stueland — Director, Officer (CHIEF EXECUTIVE OFFICER)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-16 | Option exercise/conversion | Class A Common Stock | 18,750 | — | — | 125,977 |
| 2026-09-16 | Open-market sale | Class A Common Stock | 1,648 | $94 | $155.3K | 124,329 |
| 2026-09-16 | Open-market sale | Class A Common Stock | 148 | $95 | $14.1K | 124,181 |
| 2026-09-16 | Open-market sale | Class A Common Stock | 1,525 | $97 | $147.8K | 122,656 |
| 2026-09-16 | Open-market sale | Class A Common Stock | 4,141 | $98 | $406.9K | 118,515 |
| 2026-09-16 | Open-market sale | Class A Common Stock | 3,039 | $99 | $300.8K | 115,476 |
| 2026-09-16 | Option exercise/conversion | Restricted Stock Unit | 18,750 | — | — | 37,500 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-16 | Option exercise/conversion (18,750 shares) |
| 2026-09-16 | Open-market sale (1,648 shares) |
| 2026-09-16 | Open-market sale (148 shares) |
| 2026-09-16 | Open-market sale (1,525 shares) |
| 2026-09-16 | Open-market sale (4,141 shares) |
| 2026-09-16 | Open-market sale (3,039 shares) |
| 2026-09-16 | Option exercise/conversion (18,750 shares) |
Keywords
insider transaction, Form 4, WGS, GeneDx Holdings Corp., bearish, Katherine Stueland
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.